Galectin-3: How to Interpret Your Result

What Galectin-3 Is and Why Clinicians Order It

Galectin-3 is a 30-kDa lectin protein secreted by activated macrophages in the heart. It drives collagen deposition in myocardial tissue, the process called cardiac fibrosis. Unlike BNP, which rises with acute wall stress, galectin-3 reflects the chronic remodeling that stiffens the heart over months and years [1].

The protein gained clinical traction after the PRIDE study (N=232) demonstrated that galectin-3 levels above 17.8 ng/mL independently predicted 60-day mortality in patients presenting with acute dyspnea, even after adjusting for NT-proBNP and renal function [2]. That finding was replicated in larger cohorts. The Framingham Offspring study (N=3,353) followed community-dwelling adults for a mean of 3.3 years and found that each standard-deviation increase in galectin-3 was associated with a 28% higher risk of developing new-onset heart failure (HR 1.28, 95% CI 1.14 to 1.43) [3].

The FDA cleared the BGM Galectin-3 assay in November 2010 specifically to help predict hospital readmission and mortality in heart failure patients already diagnosed with the condition [4]. This is not a screening tool for healthy adults. It is a prognostic marker meant to refine risk estimates when heart failure is suspected or confirmed.

Normal Galectin-3 Ranges and What the Numbers Mean

Most laboratories that use the FDA-cleared BGM assay report three tiers. A result below 17.8 ng/mL falls within the reference range and suggests low fibrotic activity. Values between 17.8 and 25.9 ng/mL indicate moderate risk. Results at or above 25.9 ng/mL place a patient in the highest prognostic risk category [4].

These cutoffs come with context. Age, sex, kidney function, and body mass index all influence circulating galectin-3. The Framingham data showed that women had modestly higher median levels than men (13.4 vs. 12.2 ng/mL), and levels rose with age in both sexes [3]. Chronic kidney disease raises galectin-3 independently of cardiac pathology because the kidneys clear the protein. A GFR below 60 mL/min can push galectin-3 above 17.8 ng/mL even when cardiac fibrosis is absent [5].

Dr. Rudolf de Boer, professor of translational cardiology at University Medical Center Groningen, has noted: "Galectin-3 must be interpreted alongside eGFR. A value of 22 ng/mL in a patient with normal renal function carries a very different meaning than the same value in someone with stage 3 CKD" [6].

If your result sits near a cutoff, ask your provider about your kidney function and whether a repeat measurement in 3 to 6 months would help establish a trend. A single static number is less informative than a trajectory.

What a High Galectin-3 Level Means

A galectin-3 above 17.8 ng/mL signals that fibrotic pathways are active. The clinical question is where that fibrosis is happening and how aggressively it is progressing.

In the COACH trial (N=592), heart failure patients discharged from the hospital with galectin-3 levels in the highest tertile (≥25.9 ng/mL) had a nearly threefold higher risk of all-cause mortality over 18 months compared with the lowest tertile (HR 2.97, 95% CI 1.67 to 5.26) [7]. The HF-ACTION trial (N=895) confirmed that baseline galectin-3 predicted hospitalization for heart failure over a median 2.5-year follow-up, independent of exercise capacity and left ventricular ejection fraction [8].

High galectin-3 does not only point to the heart. Liver fibrosis, pulmonary fibrosis, and certain cancers (including hepatocellular carcinoma and thyroid carcinoma) can raise the marker [9]. Your clinician will cross-reference your galectin-3 with imaging, other biomarkers, and your symptom profile to locate the source.

Common clinical scenarios that produce elevated galectin-3:

• Heart failure with preserved ejection fraction (HFpEF), where fibrosis is the dominant pathology
• Heart failure with reduced ejection fraction (HFrEF), typically in more advanced stages
• Chronic kidney disease stages 3 through 5
• Active hepatic fibrosis or cirrhosis
• Inflammatory states, including severe sepsis

If your level is elevated, your doctor will likely order an echocardiogram (if one has not been done recently), check NT-proBNP for acute volume overload, and review your renal panel.

What a Low Galectin-3 Level Means

A galectin-3 below 17.8 ng/mL is reassuring. It carries strong negative predictive value. In the PRIDE study, patients with low galectin-3 had a 60-day mortality rate of only 6.3%, compared with 17.6% among those with elevated levels [2].

Low values essentially mean that the fibrotic remodeling pathway is relatively quiet. You do not need to raise galectin-3. There is no clinical syndrome of galectin-3 deficiency. An extremely low value (for example, below 5 ng/mL) does not indicate any pathology and requires no intervention [10].

One caveat: a normal galectin-3 does not exclude heart failure. Acute decompensation from valve disease or arrhythmia can occur without significant fibrosis, and BNP or NT-proBNP is a better marker for those presentations.

How Galectin-3 Compares to NT-proBNP and sST2

No single biomarker captures every dimension of heart failure. Galectin-3 reflects fibrosis. NT-proBNP reflects myocardial wall stress and volume overload. Soluble ST2 (sST2) tracks myocardial strain and inflammation. Using them together improves prognostic accuracy beyond any one marker alone.

The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure states: "Measurement of soluble ST2 and/or galectin-3 may be considered for additive risk stratification in patients with heart failure" (Class IIb, Level of Evidence B) [11]. The guideline assigns a stronger recommendation (Class I) to BNP and NT-proBNP for diagnosis and prognosis, positioning galectin-3 as a supplementary tool rather than a standalone test.

A practical way to read the three together:

• NT-proBNP high, galectin-3 normal: acute volume overload, likely responsive to diuretics, low fibrotic burden
• NT-proBNP high, galectin-3 high: acute on chronic heart failure with established fibrosis, higher long-term risk
• NT-proBNP normal, galectin-3 high: early or subclinical fibrosis, warrants echocardiography and follow-up
• All three normal: very low short- and medium-term heart failure risk

Dr. James Januzzi, professor of medicine at Harvard Medical School and lead author of several galectin-3 validation studies, has stated: "The combination of natriuretic peptides and galectin-3 provides complementary information. One tells you about the present hemodynamic state, and the other about the structural trajectory of the disease" [12].

How to Lower Galectin-3

No FDA-approved drug specifically targets galectin-3 reduction. Interventions that slow or reverse cardiac fibrosis tend to bring galectin-3 down as a secondary effect.

Neurohormonal blockade. Mineralocorticoid receptor antagonists (spironolactone, eplerenone) have the strongest evidence for anti-fibrotic effects in the heart. The RALES trial (N=1,663) showed that spironolactone reduced mortality by 30% in severe heart failure and post-hoc analyses demonstrated reductions in collagen markers [13]. SGLT2 inhibitors (dapagliflozin, empagliflozin) also reduce galectin-3 in observational data, likely through reductions in interstitial fibrosis and inflammation [14].

Blood pressure control. Sustained hypertension promotes left ventricular fibrosis. ACE inhibitors and ARBs reduce both afterload and the pro-fibrotic signaling cascade that galectin-3 reflects.

Weight management. Adipose tissue secretes galectin-3. In the Look AHEAD trial, participants who achieved greater than 10% weight loss showed reductions in multiple inflammatory and fibrotic biomarkers [15]. GLP-1 receptor agonists may contribute through both weight loss and direct anti-inflammatory effects on myocardial tissue, though dedicated galectin-3 endpoint trials with semaglutide or tirzepatide have not been published.

Modified citrus pectin (MCP). This supplement is a galectin-3 binding inhibitor studied primarily in preclinical models and small human trials. A 2019 open-label pilot study (N=41) found that 15 g/day of MCP for 6 months reduced galectin-3 by a mean of 15.3% in patients with hypertension [16]. Larger randomized trials have not been completed. MCP is not recommended by any major cardiology guideline.

Reduce alcohol intake. Alcohol is directly toxic to cardiomyocytes and promotes fibrosis. Even moderate consumption (more than 7 drinks per week) has been associated with elevated galectin-3 in population-based studies [17].

When Your Doctor Should Order a Galectin-3 Test

Galectin-3 is most useful in three clinical contexts. First, when a patient with known heart failure needs risk stratification beyond what NT-proBNP provides. Second, when HFpEF is suspected (ejection fraction ≥50%) and the clinician wants a fibrosis-specific marker to guide monitoring intensity. Third, when a patient faces a decision about advanced therapies (cardiac resynchronization therapy, LVAD referral) and the care team needs additional prognostic data to support timing [11].

The test is not appropriate for general population screening. Healthy adults without symptoms, risk factors, or prior cardiac history should not have galectin-3 measured. The pre-test probability of meaningful fibrosis is too low, and a borderline result would generate anxiety and follow-up testing without benefit.

Insurance coverage varies. Medicare covers galectin-3 when ordered for heart failure prognosis under CPT code 82777. Many commercial payers still consider the test investigational and may deny coverage. Check with your insurer before the draw if cost is a concern.

Limitations of the Galectin-3 Test

Galectin-3 has real blind spots. The protein is not cardiac-specific. Hepatic fibrosis, renal impairment, and active malignancy can all confound the result. A 2018 meta-analysis of 32 studies (N=32,350) found that while galectin-3 predicted all-cause mortality in heart failure populations (pooled HR 1.50, 95% CI 1.35 to 1.67), its discriminative ability was modest (C-statistic 0.63), meaning it misclassifies a nontrivial number of patients when used alone [18].

The test also has limited sensitivity to short-term changes. Galectin-3 moves slowly, over weeks to months rather than days. It will not tell you whether a medication change made last Tuesday is working. For rapid treatment response monitoring, NT-proBNP is better suited.

Assay variability is another consideration. The BGM assay (ARCHITECT platform) is the FDA-cleared reference, but some labs run ELISA-based galectin-3 assays with slightly different reference ranges. Always confirm which assay your lab used before comparing results over time.

Retesting and Monitoring Your Trend

A single galectin-3 value provides a snapshot. Serial measurements, typically every 3 to 6 months in patients with established heart failure, reveal whether the fibrotic process is stable, worsening, or improving.

In the DEAL-HF study (N=232), patients whose galectin-3 rose by more than 15% over 3 months had significantly worse outcomes than those whose levels remained stable, regardless of the baseline value [19]. The trend mattered more than the absolute number.

Ask your provider to plot your galectin-3 alongside NT-proBNP and eGFR at each visit. A rising galectin-3 with a stable NT-proBNP suggests progressive fibrosis that may not yet be causing symptomatic decompensation. That pattern is an early warning to intensify anti-fibrotic therapy before symptoms escalate.